R. Lorini et al., Risk of type 1 diabetes development in children with incidental hyperglycemia - A multicenter Italian study, DIABET CARE, 24(7), 2001, pp. 1210-1216
OBJECTIVE - The aim of our study was to determine whether children with inc
idental hyperglycemia are at an increased risk of developing type 1 diabete
s.
RESEARCH DESIGN AND METHODS - A total of 748 subjects, 1-18 years of age (9
.04 +/- 3.62, mean +/- SD), without family history of type 1 diabetes, with
out obesity, and not receiving drugs were studied and found to have inciden
tal elevated glycemia defined as fasting plasma glucose >5.6 mmol/l confirm
ed on two occasions. Subjects were tested for immunological, metabolic, and
immunogenetic markers.
RESULTS - Islet cell antibodies >5 Juvenile Diabetes Foundation units were
found in 10% of subjects, elevated insulin autoantibody levels in 4.6%, GAD
antibody in 4.9%, and antityrosine phosphatase-like protein autoantibodies
in 3.9%. First-phase insulin response (FPIR) was < 1st centile in 25.6% of
subjects. The HLA-DR3/DR3 and HLA-DR4/other alleles were more frequent in
hyperglycemic children than in normal control subjects (P = 0.012 and P = 0
.005, respectively), and the HLA-DR other/other allele was less frequent th
an in normal control subjects (P = 0.000027). After a median follow-up of 4
2 months (range 1 month to 7 years), 16 (2.1%) subjects (11 males and 5 fem
ales), 4.1-13.9 years of age, became insulin dependent. All had one or more
islet autoantibodies, and the majority had impaired insulin response and g
enetic susceptibility to type 1 diabetes. Diabetes symptoms were recorded i
n 11 patients and ketonuria only in 4 patients. The cumulative risk of type
1 diabetes was similar in males and females, and it was also similar in su
bjects under or over 10 years, whereas the cumulative risk of type 1 diabet
es was increased in subjects with one or more autoantibodies and in those w
ith FPIR < 1st centile.
CONCLUSIONS - Children with incidental hyperglycemia have a higher-than-nor
mal frequency of immunological, metabolic, or genetic markers for type 1 di
abetes and have an increased risk of developing type 1 diabetes.